Skip to main content

Investigating Therapies Targeting Cardiovascular Health in MDS With Diego Adrianzen Herrera, MD

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.  

Continue reading

Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes With Claire Saxton, MBA

At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the study and ways that health care professionals and patient advocacy groups can partner to ensure that clear and consistent messages are being delivered to patients with MDS so that they can be more informed and involved in their care.  

Continue reading

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MD...

Continue reading

Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting.  

Continue reading

Pevonedistat Plus Azacitidine for Patients With Higher-Risk MDS, CMML, and AML: Mikkael A. Sekeres, MD

For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Mikkael A. Sekeres, Professor of Medicine and Chief of the Division of Hematology at the Univer...

Continue reading

Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes

In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.  

Continue reading

Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes

Amy DeZern, MD, MHS.

In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS. 

This interview has been conducted in partnership with AAMDSIF, the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, MDS, paroxysmal nocturnal hemoglobinuria, and related bone marrow failure diseases. The Foundation provides answers, support, and hope to thousands of patients and their families around the world.

Continue reading

i3 Health and Oncology Data Advisor Announce ODACon 2022, a Rare Hematologic Malignancies Symposium

ROCHELLE PARK, NJ—January 12, 2022 – i3 Health and Oncology Data Advisor have announced that ODACon, a Rare Hematologic Malignancies Symposium, will be held on January 29, 2022. This 1-day virtual conference features 5 exclusive sessions on emerging data in hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM), all presented by expert faculty. Attendees can...

Continue reading

Diagnosing Myelodysplastic Syndromes With David Steensma, MD, FACP; Reza Nejati, MD; and Ilene Galinsky, BSN, MSN, ANP-C

A complex group of heterogenous hematopoietic disorders, myelodysplastic syndromes (MDS) often go unrecognized and undiagnosed. Accurate diagnosis and risk assessment for this condition require a myriad of tests and an in-depth evaluation of symptoms. In this excerpt from their continuing medical education (CME)/nursing continuing professional development (NCPD) virtual tumor board entitled Diagnosis and Management of Myelodysplastic Syndromes, Dr. David Steensma, Dr. Reza Nejati, and Ms. Irene ...

Continue reading

Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD

In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the approval was based, discusses the challenges of treating patients with MDS and the significance of the approval of oral decitabine/cedazuridine. What a...

Continue reading

Myelodysplastic Syndromes: Decitabine/Cedazuridine Approved

The FDA has approved oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for the treatment of adult patients with either newly diagnosed or previously treated de novo or secondary myelodysplastic syndrome (MDS) whose disease is classified as one of the following French-American-British subtypes: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, or chronic myelomonocytic leukemia (CMML). Decitabine/cedazuridine is indicated for pa...

Continue reading

Myelodysplastic Syndromes: FDA Approves Luspatercept-aamt for Anemia

Patients with anemia and lower-risk myelodysplastic syndromes (MDS) are usually treated with erythropoiesis-stimulating agent therapy; however, this treatment method is not always effective in this patient population, and many rely on blood transfusions to treat MDS-related anemia. But now with the recent FDA approval of luspatercept-aamt (Reblozyl®, Celgene Corporation), those patients may no longer be dependent on blood transfusions. Luspatercept-aamt was recently FDA approved for the treatmen...

Continue reading